Reference is made to IDEX Biometrics ASA's disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share, split in two tranches.
Related Questions
How will the dilution from the 9,090,909 new shares affect earnings per share and valuation metrics?
What are the specific uses of the proceeds from the two‑tranche private placement and how will they impact IDEX Biometrics' growth strategy?
What is the pricing discount relative to the current market price and how might the market react to this financing round in the short term?